In GSK’s Hoos, Scorpion Gains Oncology Pathfinder To Match Its $270m War Chest

GSK is losing one of the principal architects of its oncology renaissance as immuno-oncology pioneer Axel Hoos prepares to leave the company for his first CEO post, at well-funded Boston cancer start-up Scorpion.